GLP-1 based drugs are transforming the treatment of obesity and opening up new avenues for addressing heart disease, addiction, and even Alzheimer’s. Now, three scientists who played key roles in their invention have won a prestigious Lasker Award for biomedical research.

Three scientists were recognized by the Lasker Awards for their work on the GLP-1 hormone. Others were honored for work to stop H.I.V. and for immune system discoveries.

This year’s prestigious Lasker medical awards recognize a trio of scientists without whom Ozempic and other blockbuster weight-loss drugs might not exist. The work of Joel Habener, a physician-investigator at the Mass General Research Institute and Harvard Medical School professor;

Three scientists are honored for developing a class of blockbuster weight-loss drugs. Is a Nobel prize on the way?

Six individuals have received this year's Lasker Awards in the areas of basic research, clinical research, and public service. Each award carries a stipend of $250,000.

Three scientists whose work paved the way to the multibillion-dollar obesity drug boom have won the Lasker Award for “the discovery and development of GLP-1-based drugs that have revolutionized the treatment of obesity,

The lauded Lasker Awards, frequently tied to Nobel Prize acclaim, highlighted the significant accomplishments of three scientists for their innovative

Weight-loss drugs like Ozempic are booming in popularity, but experts warn they aren't silver bullets for obesity.